|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.44 EUR | +0.32% |
|
-2.47% | -4.57% |
| 11-26 | CARL ZEISS MEDITEC AG : RBC reiterates its Neutral rating | ZD |
| 11-25 | Fluoguide A/S Signs Collaboration Agreement with Zeiss Medical Technologies | CI |
| Capitalization | 3.8B 4.42B 3.56B 3.32B 6.13B 398B 6.67B 41.67B 16.09B 188B 16.6B 16.25B 688B | P/E ratio 2025 * |
26.6x | P/E ratio 2026 * | 21.5x |
|---|---|---|---|---|---|
| Enterprise value | 4.24B 4.93B 3.97B 3.7B 6.84B 444B 7.44B 46.47B 17.94B 210B 18.52B 18.12B 767B | EV / Sales 2025 * |
1.93x | EV / Sales 2026 * | 1.8x |
| Free-Float |
40.86% | Yield 2025 * |
1.49% | Yield 2026 * | 1.77% |
Last Transcript: Carl Zeiss Meditec AG
| 1 day | +0.32% | ||
| 1 week | -2.47% | ||
| Current month | -2.47% | ||
| 1 month | +4.02% | ||
| 3 months | +5.03% | ||
| 6 months | -27.72% | ||
| Current year | -4.57% |
| 1 week | 42.68 |  | 45.08 |
| 1 month | 40.3 | | 46.38 |
| Current year | 40.3 | | 71.65 |
| 1 year | 40.3 | | 71.65 |
| 3 years | 40.3 | | 142.75 |
| 5 years | 40.3 | | 202 |
| 10 years | 24.66 | | 202 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 31/05/2025 | |
| Director of Finance/CFO | 60 | 30/09/2018 | |
| Chief Operating Officer | 47 | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 57 | 09/04/2018 | |
Karl Lamprecht
CHM | Chairman | 61 | 26/05/2021 |
Isabel de Paoli
BRD | Director/Board Member | 51 | 24/06/2020 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 2.71% | 0 M€ | -.--% | - |
| 0.49% | 0 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.32% | -2.47% | -25.23% | -65.23% | 4.42B | |
| -0.43% | -3.06% | +8.20% | +4.04% | 215B | |
| +1.18% | +0.32% | +4.53% | +116.04% | 204B | |
| -0.39% | -0.23% | -1.68% | -14.74% | 160B | |
| -0.20% | -4.00% | +8.27% | +115.94% | 145B | |
| +1.92% | +1.56% | -15.42% | -11.65% | 56.48B | |
| +0.48% | -0.55% | +20.49% | +19.26% | 50.02B | |
| -1.91% | -5.22% | +3.49% | -3.87% | 41.18B | |
| +3.56% | +6.84% | +5.19% | - | 38.93B | |
| +2.00% | +0.28% | +6.27% | +17.83% | 37.39B | |
| Average | +0.65% | -0.65% | +1.41% | +19.74% | 95.19B | |
| Weighted average by Cap. | +0.34% | -1.15% | +4.45% | +43.23% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.2B 2.56B 2.06B 1.92B 3.54B 230B 3.85B 24.08B 9.3B 109B 9.59B 9.39B 397B | 2.29B 2.67B 2.15B 2B 3.7B 240B 4.03B 25.14B 9.71B 113B 10.02B 9.8B 415B |
| Net income | 138M 161M 130M 121M 223M 14.5B 243M 1.52B 586M 6.85B 605M 592M 25.04B | 175M 203M 164M 153M 282M 18.31B 307M 1.92B 740M 8.65B 763M 747M 31.61B |
| Net Debt | 438M 510M 410M 383M 707M 45.88B 769M 4.8B 1.85B 21.67B 1.91B 1.87B 79.22B | 319M 371M 299M 279M 515M 33.4B 560M 3.5B 1.35B 15.78B 1.39B 1.36B 57.68B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 43.44 € | +0.32% | 73,025 |
| 04/12/25 | 43.30 € | +0.56% | 56,891 |
| 03/12/25 | 43.06 € | +0.28% | 89,494 |
| 02/12/25 | 42.94 € | -0.88% | 111,065 |
| 01/12/25 | 43.32 € | -2.74% | 214,064 |
Delayed Quote Xetra, December 05, 2025 at 04:35 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AFX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition